Bidgely Surpasses 1.5 TWh of Energy Savings, Offsetting 1M Tons of CO2 Emissions
This achievement, fueled by our financial strength, continued leadership, and dedication to consistently delivering customer value, is a milestone we are excited to share with the market.
Share
This milestone follows Bidgely's rising 'Leader' status on Guidehouse Research's latest Home Energy Management (HEM) Leaderboard, which recognized the company's expanding offerings for home energy reports (HERs), time-of-use (TOU) initiatives and managed electric vehicle (EV) charging. According to the report, ' the company's dedication to expanding its platform capabilities, reaching new clients, and delivering quality services suggests that it will remain a Leader in the HEMS market for the foreseeable future.'
The company's customer engagement strategies, including personalized consumption insights, energy profiling and behavioral load shifting, also ranked Bidgely a 'Leader' on Guidehouse Research's 2023 Customer Experience and Engagement Analytics leaderboard as well as IDC MarketScape's 2023 and 2021 Customer Engagement Vendor Assessments.
The impact of achieving over 1.5 TWh of energy savings is equal to offsetting CO2 emissions for one year from:
Over 1 billion pounds of coal burned
Nearly 2.5 million barrels of oil consumed
Nearly 121 million gallons of gas consumed
Industry-Leading Home Energy Management and Customer Engagement
Bidgely's patented disaggregation and UtilityAI™ platform helped utilities like Avista, NV Energ y, Pacific Power, PSEG Long Island, Southern California Gas among others unlock real-time energy usage insights from raw meter data to drive smarter energy consumption through a suite of customized solutions, including:
Home Energy Management Program: 360-degree view of household energy use, broken down by appliance and usage patterns.
Home Energy Reports: Personalized, dollar-based reports with easy-to-understand energy-saving recommendations.
Customer Experience & Engagement: Multi-channel customer connection via smart alerts, web portals, and call center staff equipped with one-click consumption analytics.
Combined, these tools created a journey for homeowners to gain new visibility into their highest-impact appliances in order to better focus their energy-saving efforts, i.e. adjusting thermostat settings or upgrading to more efficient appliances.
'This achievement, fueled by our financial strength, continued leadership, and dedication to consistently delivering customer value, is a milestone we are excited to share with the market,' said Bidgely CEO Abhay Gupta. 'The future of energy isn't just about grids and power—it's about people, resilience and intelligent action. Bidgely is helping create a world where utilities don't just manage demand—they anticipate and shape it.'
Beyond Energy Efficiency — Driving Greater Savings Through Smart Load Shaping
By strategically evolving and expanding its product suite, Bidgely's 1.5 TWh in energy savings is also a result of empowering utilities to boost enrollment in key load shaping and load shift programs. Bidgely's granular targeting of high-grid-impact customers unlocked the full potential of TOU rates, demand response and managed EV charging for its utility customers, while its recent GenAI integration enhances the accessibility and scalability of these programs.
'Achieving 1.5 TWh is more than a number; it's a demonstration of the future of energy management,' said Gautam Aggarwal, chief revenue officer at Bidgely. 'The precision and effectiveness of data-driven customer targeting activates unprecedented levels of efficiency and grid stability that will be instrumental for thriving in shifting dynamics of the energy industry.'
To learn why utilities are using Bidgely's AI-powered solutions to enhance energy efficiency and customer engagement, download the report: Guidehouse Research Leaderboard: Home Energy Management Systems Providers.
About Bidgely
Bidgely is an AI-powered SaaS Company accelerating a clean energy future by enabling energy companies and consumers to make data-driven energy-related decisions. Powered by our unique patented technology, Bidgely's UtilityAI™ Platform transforms multiple dimensions of customer data - such as energy consumption, demographics, and interactions - into deeply accurate and actionable consumer energy insights. We leverage these insights to empower each customer with personalized recommendations, tailored to their individual personality and lifestyle, usage attributes, behavioral patterns, purchase propensity, and beyond. From a distributed energy resources (DER) and grid edge perspective, Bidgely is advancing smart meter innovation with data-driven solutions for solar PVs, electric vehicle (EV) detection, EV behavioral load shifting and managed charging, energy theft, short-term load forecasting, grid analytics, and time of use (TOU) rate designs. Bidgely's UtilityAI™ energy analytics provides deep visibility into generation and consumption for better peak load shaping and grid planning, and delivers targeted recommendations for new value-added products and services. With roots in Silicon Valley, Bidgely has over 16 energy patents, $75M+ in funding, retains 30+ data scientists, and brings a passion for AI to utilities serving residential and commercial customers around the world. For more information, please visit www.bidgely.com or the Bidgely blog at bidgely.com/blog.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
The Open Group Launches The Open Group Open Digital Transformation™ Forum
SAN FRANCISCO--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. 'The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation,' commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. 'By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices.' Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. 'Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge,' said Steve Nunn, President and CEO of The Open Group. 'Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment.' To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries.
Business Wire
an hour ago
- Business Wire
Bureau Veritas Partners with IFC's Building Resilience Index to Expand Resilience Verification Services Globally
PARIS--(BUSINESS WIRE)-- Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), has signed the first global verifier agreement to expand the reach and impact of the Building Resilience Index (BRI). Under this agreement, Bureau Veritas will serve as a verification partner for BRI across key emerging markets in Latin America, Africa, and East Asia and the Pacific. An innovation of IFC, a member of the World Bank Group, BRI is a web-based framework designed to help developers, investors, and policymakers identify risks to buildings posed by natural hazards and assess, improve, and disclose their resilience. Through this partnership with Bureau Veritas, BRI users will gain greater access to high-quality, third-party verification of climate-resilient construction practices, expanding trust and adoption of the tool in vulnerable regions where business continuity is increasingly threatened by extreme weather and related hazards. "We are delighted to become a Global Verifier of the Building Resilience Index. As climate phenomena intensify, it has become essential to integrate climate change adaptation into assets strategy. The signing of our global agreement with the International Finance Corporation marks a crucial step,' said Marc Roussel, Executive Vice President, Urbanization and Assurance at Bureau Veritas. 'Bureau Veritas has a long history as an independent third party mitigating natural and climate risks. Our network of experts will add a layer of trust so that stakeholders can rely on Building Resilience Index to evaluate vulnerability and effectiveness of adaptation strategies, worldwide.' In recent years, physical risks such as floods, cyclones, heatwaves, fires, earthquakes and landslides have posed major threats to business operations, disrupting supply chains, displacing workers and jobs, hurting productivity, and impacting insurance and financing terms. The BRI-Bureau Veritas partnership responds to a growing demand from businesses and governments for reliable tools that support risk mitigation, asset protection, and long-term economic stability. 'As businesses face increased risks to assets and infrastructure from natural disasters, the ability to assess and verify resilience is becoming a crucial element of operational and investment strategy,' said Diep Nguyen-van Houtte, Senior Manager of Climate Business at IFC. 'This partnership with Bureau Veritas strengthens the Building Resilience Index by ensuring that more clients—particularly in high-risk geographies—can benefit from credible, independently-verified insights into the resilience of their properties, adding a new tool to their climate adaptation arsenal.' By offering third-party verification through Bureau Veritas, the Building Resilience Index helps stakeholders: Protect operational continuity by identifying risks early and designing for resilience Safeguard jobs and livelihoods by minimizing disruption in vulnerable communities Enhance access to capital through better risk ratings and insurance alignment Improve public trust and accountability through independent performance validation This partnership builds on IFC's broader commitment to integrating adaptation into private sector development and enabling practical, market-driven solutions for climate resilience. BRI is funded by the Australian Government and was developed and piloted with seed funding from the Government of the Netherlands and the Rockefeller Foundation, in cooperation with leading organizations including the ARISE Private Sector Alliance for Disaster Resilient Societies, Build Change, FM Global, the Global Facility for Disaster Reduction and Recovery, Miyamoto International, and Resilience Action Fund. About Bureau Veritas: Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers' excellence and sustainability, the company innovates to help them navigate change. Created in 1828, Bureau Veritas' 84,000 employees deliver services in 140 countries. The company's technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability. Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI. For more information, visit and follow us on LinkedIn. About IFC: IFC — a member of the World Bank Group — is the largest global development institution focused on the private sector in emerging markets. We work in more than 100 countries, using our capital, expertise, and influence to create markets and opportunities in developing countries. In fiscal year 2024, IFC committed a record $56 billion to private companies and financial institutions in developing countries, leveraging private sector solutions and mobilizing private capital to create a world free of poverty on a livable planet. For more information, visit
Business Wire
an hour ago
- Business Wire
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
LYON, France--(BUSINESS WIRE)--Regulatory News: We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg ®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants. With robust cGMP manufacturing, proprietary therapies, and a development platform, MaaT Pharma is a global leader in microbiome-based oncology, pioneering full-ecosystem therapies to improve survival in oncology. Since completing enrollment in the ARES trial for Xervyteg ® (MaaT013) in October 2024, MaaT Pharma has steadily advanced its roadmap, reporting topline results in January 2025, submitting the Marketing Authorization Application with the European Medicines Agency in June 2025, and signing an exclusive agreement for marketing and distribution in Europe with Clinigen in July 2025. The €37.5 million financing from the EIB follows a rigorous due diligence process by the EIB and further confirms MaaT Pharma's innovation, strategic vision and operational maturity. This funding is part of a global financial strategy to support the Company's development that combines various non-dilutive and dilutive sources to best preserve shareholder value. Eric Soyer, Chief Financial Officer, MaaT Pharma, said: 'We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg ® (MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company's financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy.' Summary of the main terms and conditions of the Loan and Warrants The loan would be available in four (4) tranches, respectively of €3.5 million for Tranche A, €6.0 million for Tranche B, €8.0 million for Tranche C, and €20.0 million for Tranche D, each tranche with Warrants attached. Disbursement of Tranches 2 to 4 are subject to operational and financing conditions. All Tranches are redeemable after a grace period of 4 years from the date of drawing, with reimbursement over a period of 2 years (Tranche A, B and C, i.e. a maturity of 6 years) to 4 years (Tranche D, i.e. a maturity of 8 years). Each tranche will bear interests at 7%, it being provided that some interests will be deferred and paid at maturity and for Tranche C and Tranche D part of the interest will be paid quarterly. MaaT Pharma will issue warrants to the benefit of EIB at the time of (and subject to) disbursement of each tranche in a number depending, for each relevant tranche, on the amount of the relevant tranche and the average price per share paid by investors in the context of equity injection made prior to disbursement of the relevant tranche (except for tranche A where the average price per share over the last trading days preceding the date of execution of the financing agreement). Each warrant will give right to subscribe to one share at a price per warrant equal to 99% of the average price over a period of 5 trading days preceding the issuance of each Warrant. The Warrants may be exercised at any time following maturity of Tranche A. The Warrants will have a 20-year term. EIB and MaaT Pharma have also agreed on (i) a put option to the benefit of EIB under which MaaT Pharma undertook to acquire from EIB all or part of the Warrants upon occurrence of certain events and (ii) a call option to the benefit of MaaT Pharma under which EIB undertook to sell all its Warrants, upon occurrence of a public tender offer over the securities issued by MaaT Pharma. The Warrants are not transferable, except to affiliates of EIB or except in case of occurrence of certain events (including maturity date of Tranche D). In case of transfer of Warrants to third party, MaaT Pharma shall benefit from a preemptive right to acquire the Warrants first. MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor. About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
